We are a preclinical-stage biotechnology spin-off from Chulalongkorn University, focusing on novel gene-edited immune cell products for cancer treatment. Our mission is to improve CAR T cell treatment outcomes in solid tumors by overcoming immune suppression within the tumor niche using our PLUS CAR T technology. We’ve integrated our proprietary endodomain into second-generation CAR constructs, significantly enhancing cellular proliferation, cytotoxicity, and persistence while reducing exhaustion. Our CAR T cell platform can effectively target multiple solid tumor types, potentially transforming solid tumor therapy.